SCOPUS 정보 검색 플랫폼

Investigational New Drugs

Volumn 15, Issue 2, 1997, Pages 147-151

Early clinical investigation of sulofenur with a daily schedule in advanced solid tumours

(5) Krarup Hansen, Anders a Pedersen, Hans a Andersen, Elo a Andersen, Helle a Hansen, Heine a

a FINSEN LABORATORY (Denmark)

Author keywords

Daily schedule; Phase I trial; Solid tumours; Sulofenur

Indexed keywords

LACTATE DEHYDROGENASE; SULFONYLUREA; SULOFENUR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; HEMOLYTIC ANEMIA; HUMAN; METHEMOGLOBINEMIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TOXIC HEPATITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SULFONYLUREA COMPOUNDS;

EID: 0030976380 PISSN: 01676997 EISSN: None Source Type: Journal
DOI: 10.1023/A:1005864907544 Document Type: Article

Times cited : (2)

References (11)

1
- 0000126439
- Identification of diarylsulfonureas as novel anticancer drugs
- Grindey GB: Identification of diarylsulfonureas as novel anticancer drugs. Proc Am Assoc Cancer Res 29:535, 1988
- (1988) Proc Am Assoc Cancer Res , vol.29 , pp. 535
- Grindey, G.B.¹

2
- 84969065552
- Evaluation of 5-(indianylsulfonyl)-N-(4-chlorophenyl)urea (LY186641) against advanced state xenografts childhood rhabdomyosarcoma
- Haughton PJ, Myers L, Cheshire P, Grinde GB, Haughton JA: Evaluation of 5-(indianylsulfonyl)-N-(4-chlorophenyl)urea (LY186641) against advanced state xenografts childhood rhabdomyosarcoma. Proc Am Ass Cancer Res 30:A2203, 1989
- (1989) Proc Am Ass Cancer Res , vol.30
- Haughton, P.J.¹ Myers, L.² Cheshire, P.³ Grinde, G.B.⁴ Haughton, J.A.⁵

3
- 0011950933
- Mechanism of action studies with LY 186641
- Boder GB, Beasley FW, Grindey DB: Mechanism of action studies with LY 186641. Proc Am Assoc Cancer Res 30:A2203, 1989
- (1989) Proc Am Assoc Cancer Res , vol.30
- Boder, G.B.¹ Beasley, F.W.² Grindey, D.B.³

4
- 8244238433
- Indianapolis: Lilly research
- Lilly Research: LY 186641 (Sulfonylurea). Clinical investigation manual. Indianapolis: Lilly research 1.0-8.1, 1993
- (1993) LY 186641 (Sulfonylurea). Clinical Investigation Manual , pp. 10-81
- Research, L.¹

5
- 0024430907
- Clinical pharmacology of a novel diarylsulfonylurea anticancer agent
- Taylor CW, Alberts DS, Ketcham MA, Satterlee WG, Holdsworth MT, Plezia PM, Peng Y-M, McCloskey TM, Roe DJ, Hamilton M, Salmon SE: Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. J Clin Oncol 7:1733-1740, 1989
- (1989) J Clin Oncol , vol.7 , pp. 1733-1740
- Taylor, C.W.¹ Alberts, D.S.² Ketcham, M.A.³ Satterlee, W.G.⁴ Holdsworth, M.T.⁵ Plezia, P.M.⁶ Peng, Y.-M.⁷ McCloskey, T.M.⁸ Roe, D.J.⁹ Hamilton, M.¹⁰ Salmon, S.E.¹¹

6
- 0028358310
- Phase I trial of Solufenur (LY 186641) given orally on a daily X 21 schedule
- Brown TD, O'Rourke TJ, Kuhn JG, Craig JB, Havlin K, Burris III HA, Cagnola J, Hamilton JM, Grindey GB, Satterlee WG, Von Hoff DD: Phase I trial of Solufenur (LY 186641) given orally on a daily X 21 schedule. Anti-Cancer Drugs 5: 151-159, 1994
- (1994) Anti-Cancer Drugs , vol.5 , pp. 151-159
- Brown, T.D.¹ O'Rourke, T.J.² Kuhn, J.G.³ Craig, J.B.⁴ Havlin, K.⁵ Burris III, H.A.⁶ Cagnola, J.⁷ Hamilton, J.M.⁸ Grindey, G.B.⁹ Satterlee, W.G.¹⁰ Von Hoff, D.D.¹¹

7
- 0024417322
- Phase I clinical study of N((4-chlorophenyl)amino) carbonyl-2,3-dihydro-lHindene-5-sulfonamide (LY 186641)
- Hainsworth JD, Hande KR, Satterlee WG, Kuttesch J, Johnson DH, Grindey G, Jackson LE, Greco FA: Phase I clinical study of N((4-chlorophenyl)amino) carbonyl-2,3-dihydro-lHindene-5-sulfonamide (LY 186641). Cancer Res 49:5217-5220, 1989
- (1989) Cancer Res , vol.49 , pp. 5217-5220
- Hainsworth, J.D.¹ Hande, K.R.² Satterlee, W.G.³ Kuttesch, J.⁴ Johnson, D.H.⁵ Grindey, G.⁶ Jackson, L.E.⁷ Greco, F.A.⁸

8
- 0026693909
- A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer
- O'Brien MER, Hardy J, Tan S, Walling J, Peters B, Hatty S, Wiltshaw E: A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer. Cancer Chemother Pharmacol 30:245-248, 1992
- (1992) Cancer Chemother Pharmacol , vol.30 , pp. 245-248
- O'Brien, M.E.R.¹ Hardy, J.² Tan, S.³ Walling, J.⁴ Peters, B.⁵ Hatty, S.⁶ Wiltshaw, E.⁷

9
- 0027522619
- Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer
- Talbot DC, Smith, IE, Nicolson, MC, Powles TJ, Button D, Walling J: Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer. Cancer Chemother Pharmacol 31:419-422, 1993
- (1993) Cancer Chemother Pharmacol , vol.31 , pp. 419-422
- Talbot, D.C.¹ Smith, I.E.² Nicolson, M.C.³ Powles, T.J.⁴ Button, D.⁵ Walling, J.⁶

10
- 0027215746
- Phase II study of sulofenur (LY186641). A novel antineoplstic agent in advanced non-small cell lung cancer
- Munshi, NC, Seitz DE, Fossella F, Lippmann SM, Einhorn LH: Phase II study of sulofenur (LY186641). A novel antineoplstic agent in advanced non-small cell lung cancer. Invest New Drugs 11:87-90, 1993
- (1993) Invest New Drugs , vol.11 , pp. 87-90
- Munshi, N.C.¹ Seitz, D.E.² Fossella, F.³ Lippmann, S.M.⁴ Einhorn, L.H.⁵

11
- 0026707523
- A phase II study of sulofenur (LY 1886641) in gastric cancer
- Kamthan A, Scarffe JH, Walling J, Hatty S, Peters B, Coleman R, Smyth JF: A phase II study of sulofenur (LY 1886641) in gastric cancer. Anti-Cancer Drugs 3:331-335, 1992
- (1992) Anti-Cancer Drugs , vol.3 , pp. 331-335
- Kamthan, A.¹ Scarffe, J.H.² Walling, J.³ Hatty, S.⁴ Peters, B.⁵ Coleman, R.⁶ Smyth, J.F.⁷

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.